Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ia Dose-escalation Study to Access the Tolerability Safety Pharmacokinetics and Pharmacodynamics of Recombinant Human Thrombopoietin in the Patients With Different Degree of Liver Function Impairment

Trial Profile

A Phase Ia Dose-escalation Study to Access the Tolerability Safety Pharmacokinetics and Pharmacodynamics of Recombinant Human Thrombopoietin in the Patients With Different Degree of Liver Function Impairment

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 25 Sep 2018

At a glance

  • Drugs Thrombopoietin (Primary)
  • Indications Aplastic anaemia; Idiopathic thrombocytopenic purpura; Thrombocytopenia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Shenyang Sunshine Pharmaceutical
  • Most Recent Events

    • 25 Sep 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top